• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket

    12/20/22 6:13:15 AM ET
    $ADXN
    $APCX
    $AXLA
    $BXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $ADXN alert in real time by email

    Gainers

    • IceCure Medical Ltd (NASDAQ:ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.
    • Exicure, Inc. (NASDAQ:XCUR) shares rose 46% to $1.08 in pre-market trading. Exicure 10% owner CBI USA, Inc. acquired a total of 3,400,000 shares at an average price of $1.60.
    • Verona Pharma plc (NASDAQ:VRNA) rose 39.3% to $18.80 in pre-market trading after the company reported positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.
    • Otonomy, Inc (NASDAQ:OTIC) rose 28.6% to $0.1475 in pre-market trading after the company issued a corporate update. The company said it approved and adopted plan of liquidation and dissolution, to include distribution of remaining cash to stockholders following orderly wind down of company's operations.
    • Inovio Pharmaceuticals, Inc. (NASDAQ:INO) rose 18.5% to $1.85 in pre-market trading after dropping over 13% on Monday.
    • Healthcare Triangle, Inc. (NASDAQ:HCTI) rose 18.4% to $0.3079 in pre-market trading after declining 16% on Monday. Healthcare Triangle, last month, posted a Q3 loss of $0.06 per share.
    • Metacrine, Inc. (NASDAQ:MTCR) rose 17% to $0.4098 in pre-market trading. Tang Capital Partners reported in 13G filing a 7.1% stake in Metacrine.
    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares rose 16.5% to $0.3650 in pre-market trading. Vallon Pharmaceuticals and GRI Bio recently announced they entered into a merger agreement.
    • Sumitomo Mitsui Financial Group, Inc. (NYSE:SMFG) rose 16% to $7.97 in pre-market trading.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) rose 15% to $0.69 in pre-market trading.
    • Surrozen, Inc. (NASDAQ:SRZN) rose 12.5% to $0.5406 in pre-market trading after gaining 8% on Monday.
    • Mitsubishi UFJ Financial Group, Inc. (NYSE:MUFG) rose 12.6% to $6.25 in pre-market trading.
    • OpGen, Inc. (NASDAQ:OPGN) rose 12.5% to $0.1475 in pre-market trading. OpGen recently announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
    • Smart for Life, Inc. (NASDAQ:SMFL) rose 11.5% to $0.2234 in pre-market trading after dropping 22% on Monday.
    • Baudax Bio, Inc. (NASDAQ:BXRX) rose 10.9% to $2.04 in pre-market trading. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery.
    • NextDecade Corporation (NASDAQ:NEXT) shares rose 10.1% to $4.55 in pre-market trading after dipping 7% on Monday.
    • Icosavax, Inc. (NASDAQ:ICVX) rose 8.1% to $9.77 in pre-market trading after declining 9% on Monday. The company recently provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus


    Don’t forget to check out our premarket coverage here .


    Losers

    • Entrada Therapeutics Inc (NASDAQ:TRDA) fell 32.1% to $13.50 in pre-market trading after the company said it received a clinical hold notice from the FDA regarding its Investigational New Drug Application for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.
    • Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares fell 24.3% to $1.40 in pre-market trading. Soleno Therapeutics shares jumped around 104% on Monday after the company announced a financing commitment for up to $60 million..
    • Axcella Health Inc. (NASDAQ:AXLA) shares fell 22.7% to $0.3321 in pre-market trading after gaining 165% on Monday. Axcella Health recently announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) fell 20.5% to $0.1410 in pre-market trading after dropping 13% on Monday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
    • Camber Energy, Inc. (NYSE:CEI) fell 19.1% to $0.0867 in pre-market trading. Camber Energy shares jumped 73% on Monday after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split.
    • Caravelle International Group (NASDAQ:CACO) fell 17.7% to $3.94 in pre-market trading after declining over 12% on Monday.
    • EUDA Health Holdings Limited (NASDAQ:EUDA) fell 17.4% to $1.32 in pre-market trading after dropping more than 10% on Monday.
    • Hoth Therapeutics, Inc. (NASDAQ:HOTH) fell 16.5% to $2.46 in pre-market trading after dropping 14% on Monday. Hoth Therapeutics recently announced submission of investigational new drug application for HT-001.
    • NantHealth, Inc. (NASDAQ:NH) shares fell 15.9% to $3.54 in pre-market trading after dropping 26% on Monday. NantHealth recently announced a 1-for-15 reverse stock split.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) shares fell 13.3% to $0.7125 in pre-market trading after jumping 49% on Monday.
    • Reed's, Inc. (NASDAQ:REED) fell 13% to $0.0879 in pre-market trading after gaining around 35% on Monday.
    • AppTech Payments Corp. (NASDAQ:APCX) fell 10.8% to $1.25 in pre-market trading after jumping 55% on Monday.
    • Shift Technologies, Inc. (NASDAQ:SFT) fell 10.2% to $0.16 in pre-market trading after declining around 7% on Monday.
    • Gaotu Techedu Inc. (NASDAQ:GOTU) fell 7.1% to $3.01 in pre-market trading. Gaotu Techedu, last month, reported a third-quarter FY22 sales decline of 45.6% year-on-year to RMB606.2 million ($85.21 million).
    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $APCX
    $AXLA
    $BXRX

    CompanyDatePrice TargetRatingAnalyst
    NextDecade Corporation
    $NEXT
    3/5/2026$7.00 → $6.00Hold
    TD Cowen
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    NextDecade Corporation
    $NEXT
    2/6/2026$7.00Overweight
    CapitalOne
    Entrada Therapeutics Inc.
    $TRDA
    1/28/2026$21.00Outperform
    Oppenheimer
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    NextDecade Corporation
    $NEXT
    10/23/2025$8.00 → $7.00Hold
    TD Cowen
    Soleno Therapeutics Inc.
    $SLNO
    10/7/2025$125.00Buy
    Goldman
    More analyst ratings

    $ADXN
    $APCX
    $AXLA
    $BXRX
    SEC Filings

    View All

    SEC Form 10-K filed by Hoth Therapeutics Inc.

    10-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

    3/27/26 4:58:52 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXICURE, INC. (0001698530) (Filer)

    3/27/26 4:40:30 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Reed's Inc.

    8-K - REED'S, INC. (0001140215) (Filer)

    3/27/26 4:05:12 PM ET
    $REED

    $ADXN
    $APCX
    $AXLA
    $BXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen reiterated coverage on NextDecade with a new price target

    TD Cowen reiterated coverage of NextDecade with a rating of Hold and set a new price target of $6.00 from $7.00 previously

    3/5/26 7:46:59 AM ET
    $NEXT
    Oil & Gas Production
    Utilities

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Entrada Therapeutics with a new price target

    Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00

    2/11/26 7:51:55 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $APCX
    $AXLA
    $BXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

    NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computational platform designed to accelerate drug discovery, enhance data-driven decision-making, and unlock value across its therapeutic pipeline. OpenClaw™ Activation Marks Strategic Shift Toward AI-Driven Drug DevelopmentThe launch of OpenClaw™ establishes a centralized, high-performance platform capable of integrating preclinical and clinical datasets in real time, enabling faster and

    3/26/26 8:30:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

    CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent fees and other offering expenses. In addition, in a concurrent private pla

    3/26/26 8:00:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $APCX
    $AXLA
    $BXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Derosa Thomas Joseph bought $3,299 worth of shares (10,000 units at $0.33), increasing direct ownership by 22% to 56,096 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    3/5/26 4:58:08 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Lord Albert L bought $9,578 worth of shares (29,606 units at $0.32), increasing direct ownership by 0.91% to 3,300,000 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    3/5/26 4:57:43 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    $ADXN
    $APCX
    $AXLA
    $BXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tcg Crossover Gp Ii, Llc

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/25/26 8:02:09 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Malca Yonatan

    3 - IceCure Medical Ltd. (0001584371) (Issuer)

    3/25/26 5:16:30 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Huang Yang

    3 - IceCure Medical Ltd. (0001584371) (Issuer)

    3/25/26 5:15:46 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ADXN
    $APCX
    $AXLA
    $BXRX
    Leadership Updates

    Live Leadership Updates

    View All

    IceCure Appoints Meir Peleg as Chief Financial Officer

    Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr. Meir Peleg as its Chief Financial Officer ("CFO"), effective May 17, 2026. The appointment comes as IceCure is

    3/24/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ADXN
    $APCX
    $AXLA
    $BXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Reeds Inc.

    SC 13D/A - REED'S, INC. (0001140215) (Subject)

    12/6/24 4:30:32 PM ET
    $REED

    Amendment: SEC Form SC 13D/A filed by Reeds Inc.

    SC 13D/A - REED'S, INC. (0001140215) (Subject)

    12/4/24 6:11:30 AM ET
    $REED

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $APCX
    $AXLA
    $BXRX
    Financials

    Live finance-specific insights

    View All

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reed's Reports Fourth Quarter and Full Year 2025 Results; Announces Leadership Transition

    Profitable Growth Initiatives Lead to Sequential Quarterly Improvement  Neal Cohane Appointed Interim Chief Executive Officer NORWALK, Conn., March 24, 2026 (GLOBE NEWSWIRE) -- Reed's, Inc. (NYSE:REED) ("Reed's" or the "Company"), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three months and 12 months ended December 31, 2025. Additionally, the Company announced that Neal Cohane has been appointed to serve as interim Chief Executive Officer and member of the board of directors, effective today. Former CEO and Board Member Cyril Wallace has stepped down. The board has begun conducting a search for a permanent CE

    3/24/26 4:05:00 PM ET
    $REED

    IceCure Reports 2025 Full Year Financial & Operational Results

    Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectivelyStrong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customersIceCure Applies to Expand Regulatory Approval in Canada for ProSense® Cryoablation to Include the Treatment of Low-Risk Breast Cancer  Conference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the

    3/17/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care